AI-generated · cited to primary sources · not investment advice
Neogen Chemicals (542665) Nov 2025 Filing Analysis
Does management do what it says?
Standalone Q1 FY27 EBITDA margin was 19.1%, within the guided 16.5%-19.5% range and near the 18% target. (1 met across 1 tracked commitment)
“next year, when we hit full utilization, INR 950 crore to INR 1,000 crore on standalone basis, we expect the same (margin) - 18% plus or minus one, 1%, 1.5% margin. And then as we get further utilization, as we go into FY28, maybe improvement over that.”
See the full cited Management analysis of Neogen Chemicals
What could break the thesis?
The competitive risk has eased somewhat from the prior quarter because Chinese prices have firmed and some loss-making producers have shut down. However, Chinese supply remains the benchmark, and customers can still choose imported salt or electrolyte when it is cheaper. The risk therefore remains high rather than resolved. (2 easing, 1 stable)
“Some of these companies were not able to sustain and started closing down. Also, the demand situation is looking better. The overcapacity in China ... is now no longer there ... Therefore, we have seen, firming up of battery material prices, as well as electrolyte, electrolyte salt and to some extent, even cell costs are also likely to go up over the coming year.”
See the full cited Risk analysis of Neogen Chemicals
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.